Approval · Notice of Compliance 20231 · 2018
MOSASPRAY: Notice of Compliance 20231
Issued January 3, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 20231
- Date
- January 3, 2018
- Company
- Sandoz Canada Inc.Saint-Hubert, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to inner and outer label
- Canadian reference product
- NASONEX ALLERGY AND CONGESTION (Schering-Plough Canada Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MOSASPRAY | Not yet assigned | — |
Medicinal ingredients
- MOMETASONE FUROATE MONOHYDRATE 50 MCG per ACT